#VisualAbstract: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. ...
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. ...
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. ...
Recent advances have been demonstrated with the administration of intraperitoneal (IP) cisplatin and paclitaxel, where women with stage III ovarian ...
1. In a phase II trial of T3 resectable rectal cancer, adding bevacizumab to induction and neoadjuvant chemoradiation resulted in ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.